BGLC vs QDEL

For growth investors, QuidelOrtho Corporation (QDEL) is the stronger pick with -1.

9% revenue growth year-over-year, versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). Analysts rate QuidelOrtho Corporation (QDEL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, QuidelOrtho Corporation (QDEL) delivered a total return of -91.

1%, compared to -98. 6% for BioNexus Gene Lab Corp. (BGLC). Over 10 years, the gap is even starker: QDEL returned -34. 9% versus BGLC's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioNexus Gene Lab Corp.

(BGLC) is the lower-risk stock at 1. 55β versus QuidelOrtho Corporation's 2. 59β — meaning QDEL is approximately 67% more volatile than BGLC relative to the S&P 500. On balance sheet safety, BioNexus Gene Lab Corp. (BGLC) carries a lower debt/equity ratio of 3% versus 146% for QuidelOrtho Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), QuidelOrtho Corporation (QDEL) is pulling ahead at -1.

9% versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). On earnings-per-share growth, the picture is similar: QuidelOrtho Corporation grew EPS 45. 4% year-over-year, compared to 41. 2% for BioNexus Gene Lab Corp.. Over a 3-year CAGR, QDEL leads at -5. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BioNexus Gene Lab Corp.

(BGLC) is the more profitable company, earning -16. 8% net margin versus -41. 5% for QuidelOrtho Corporation — meaning it keeps -16. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BGLC leads at -16. 5% versus -33. 7% for QDEL. At the gross margin level — before operating expenses — QDEL leads at 46. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioNexus Gene Lab Corp.

(BGLC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BGLC: -99. 2%, QDEL: -34. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.